Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 513Breast Neoplasms, Male 79Ovarian Neoplasms 54Triple Negative Breast Neoplasms 46Lung Neoplasms 43Colonic Neoplasms 41Prostatic Neoplasms 38Neoplasms 38Neoplasm Metastasis 35Carcinoma, Non-Small-Cell Lung 33Melanoma 31Pancreatic Neoplasms 29Colorectal Neoplasms 28Stomach Neoplasms 24Carcinoma, Ovarian Epithelial 24Endometrial Neoplasms 23Carcinoma, Renal Cell 23Inflammatory Breast Neoplasms 21Brain Neoplasms 20Carcinoma, Intraductal, Noninfiltrating 19Breast Carcinoma In Situ 19Rectal Neoplasms 18Urinary Bladder Neoplasms 17Lymphoma, Non-Hodgkin 17Lymphoma, T-Cell, Cutaneous 16Leukemia, Lymphocytic, Chronic, B-Cell 16Esophageal Neoplasms 16Uterine Cervical Neoplasms 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lymphoma 15

Interventions

Magnetic Resonance Spectroscopy 116-fluoroestradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × HER2/Neu Negative × Breast × Clear all
NCT02398773 2026-04-21

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

National Cancer Institute (NCI)

Phase 2 Active not recruiting
99 enrolled
Breast

HER2/Neu Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡